KorrekturOpen Access
Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”
International Forum of Allergy & Rhinology · 2026-06 · 16 (6) · 654-655
DOI: 10.1002/alr.70172 ↗Kurz gefasst
Korrektur in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 11.05.2026. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology, 16(6), 654-655. https://doi.org/10.1002/alr.70172
Vancouver
Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology. 2026;16(6):654-655. doi:10.1002/alr.70172
BibTeX
@article{euvimed2026,
title = {Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
volume = {16},
number = {6},
pages = {654--655},
doi = {10.1002/alr.70172}
}
EUVIMED